Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients
| Autor: | Jesus Miguens Blanco, Jonathan Hurtado, Benjamin H. Mullish, Grace F. Barker, Julian Marchesi, Isabel Garcia-Perez, Madeline Carrellas, Julie A. K. McDonald, Alexandros Pechlivanis, Jessica R. Allegretti, Zain Kassam, Austin Chiang, Michael Silverstein, Christopher C. Thompson, Kevin Kennedy, Ylaine Gerardin, Wing Fei Wong |
|---|---|
| Přispěvatelé: | Medical Research Council, Medical Research Council (MRC), Imperial College Healthcare NHS Trust- BRC Funding |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Capsules Pilot Projects Placebo GUT MICROBIOME Gastroenterology Feces Mice Bile Acids 03 medical and health sciences 0302 clinical medicine INTESTINAL MICROBIOTA Diabetes mellitus Internal medicine medicine Animals Humans Microbe Obesity STRATEGY Science & Technology Gastroenterology & Hepatology Bacteria Hepatology Bile acid INSULIN SENSITIVITY Maintenance dose business.industry Area under the curve 1103 Clinical Sciences Fecal Microbiota Transplantation Overweight medicine.disease Glucagon-like peptide-1 Gastrointestinal Microbiome Treatment Treatment Outcome 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Metabolic syndrome business Life Sciences & Biomedicine Body mass index |
| Zdroj: | 863.e2 |
| ISSN: | 1542-3565 |
| DOI: | 10.1016/j.cgh.2019.07.006 |
| Popis: | Background & Aims Studies in mice have shown that the intestinal microbiota can contribute to obesity via the anorexigenic gut hormone glucagon-like peptide 1 (GLP1) and bile acids, which affect lipid metabolism. We performed a randomized, placebo-controlled pilot study of the effects of fecal microbiota transplantation (FMT) in obese, metabolically uncompromised patients. Methods We performed a double-blind study of 22 obese patients (body mass index [BMI] ≥ 35kg/m2) without a diagnosis of diabetes, non-alcoholic steatohepatitis, or metabolic syndrome. Participants were randomly assigned (1:1) to groups that received FMT by capsules (induction dose of 30 capsules at week 4 and maintenance dose of 12 capsules at week 8) or placebo capsules. FMT capsules were derived from a single, lean donor (BMI, 17.5 kg/m2). Patients were followed through week 26; the primary outcome was safety. Stool and serum samples were collected from patients at baseline and at weeks 1, 4, 6, 8 and 12 after administration of the first dose of FMT or placebo and analyzed by 16S RNA gene sequencing. Stool and serum samples were analyzed for metabolomics by liquid chromatography-mass spectrometry. Additional outcomes were change in area under the curve for GLP1 at week 12. Results We observed no significant differences in adverse events between patients who received FMT vs placebo. There was no increase in the area under the curve of GLP1 in either group. Patients who received FMT had sustained shifts in microbiomes associated with obesity toward those of the donor (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|